ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,705 | -49.0% | 8,984 | -8.5% | 0.00% | – |
| Q2 2023 | $93,537 | +3.5% | 9,815 | +19.4% | 0.00% | – |
| Q1 2023 | $90,387 | -56.3% | 8,217 | -41.2% | 0.00% | – |
| Q4 2022 | $206,904 | +13.1% | 13,980 | +46.2% | 0.00% | – |
| Q3 2022 | $183,000 | +226.8% | 9,565 | +261.2% | 0.00% | – |
| Q2 2022 | $56,000 | +55.6% | 2,648 | +76.5% | 0.00% | – |
| Q3 2021 | $36,000 | -10.0% | 1,500 | 0.0% | 0.00% | – |
| Q2 2021 | $40,000 | – | 1,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |